166 related articles for article (PubMed ID: 32952659)
1. Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Miyake M; Oda Y; Nishimura N; Morizawa Y; Ohnishi S; Hatakeyama K; Fujii T; Hori S; Gotoh D; Nakai Y; Anai S; Torimoto K; Tsukamoto S; Fujii H; Kido A; Honoki K; Matsumura Y; Okajima E; Tanaka N; Fujimoto K
Oncol Lett; 2020 Nov; 20(5):190. PubMed ID: 32952659
[TBL] [Abstract][Full Text] [Related]
2. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma.
Yang X; Zhu G; Yang Z; Zeng K; Liu F; Sun J
Int J Biol Markers; 2018 Nov; 33(4):507-513. PubMed ID: 29862874
[TBL] [Abstract][Full Text] [Related]
6. Status of programmed death-ligand 1 expression in sarcomas.
Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
[TBL] [Abstract][Full Text] [Related]
7. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence.
Cui L; Tian X; Yan L; Guan X; Dong B; Zhao M; Lv A; Liu D; Wu J; Hao C
Int J Med Sci; 2022; 19(13):1977-1988. PubMed ID: 36438917
[No Abstract] [Full Text] [Related]
8. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
Boxberg M; Steiger K; Lenze U; Rechl H; von Eisenhart-Rothe R; Wörtler K; Weichert W; Langer R; Specht K
Oncoimmunology; 2018; 7(3):e1389366. PubMed ID: 29399389
[TBL] [Abstract][Full Text] [Related]
9. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
Front Oncol; 2019; 9():883. PubMed ID: 31572677
[TBL] [Abstract][Full Text] [Related]
10. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
11. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
12. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer.
Xue C; Zhu D; Chen L; Xu Y; Xu B; Zhang D; Jiang J
Transl Cancer Res; 2019 Feb; 8(1):111-119. PubMed ID: 35116740
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
15. GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Koh YW; Han JH; Park SY; Yoon DH; Suh C; Huh J
J Pathol Transl Med; 2017 Mar; 51(2):152-158. PubMed ID: 28219001
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
18. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression.
Chae H; Kim JE; Kim W; Lee JS; Song SY; Lee MH; Chung HW; Cho KJ; Song JS; Ahn JH
Cancer Res Treat; 2022 Apr; 54(2):579-589. PubMed ID: 34237209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]